Biological Activity of High-Purity β-1,3-1,6-Glucan Derived from the Black Yeast Aureobasidium pullulans: A Literature Review. 2021

Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
Research and Development Laboratories, Fujicco, Co., Ltd., 6-13-4 Minatojima-Nakamachi, Chuo-ku, Kobe, Hyogo 650-8558, Japan.

The black yeast Aureobasidium pullulans produces abundant soluble β-1,3-1,6-glucan-a functional food ingredient with known health benefits. For use as a food material, soluble β-1,3-1,6-glucan is produced via fermentation using sucrose as the carbon source. Various functionalities of β-1,3-1,6-glucan have been reported, including its immunomodulatory effect, particularly in the intestine. It also exhibits antitumor and antimetastatic effects, alleviates influenza and food allergies, and relieves stress. Moreover, it reduces the risk of lifestyle-related diseases by protecting the intestinal mucosa, reducing fat, lowering postprandial blood glucose, promoting bone health, and healing gastric ulcers. Furthermore, it induces heat shock protein 70. Clinical studies have reported the antiallergic and triglyceride-reducing effects of β-1,3-1,6-glucan, which are indicators of improvement in lifestyle-related diseases. The primary and higher-order structures of β-1,3-1,6-glucan have been elucidated. Specifically, it comprises a single highly-branched glucose residue with the β-1,6 bond (70% or more) on a backbone of glucose with 1,3-β bonds. β-Glucan shows a triple helical structure, and studies on its use as a drug delivery system have been actively conducted. β-Glucan in combination with anti-inflammatory substances or fullerenes can be used to target macrophages. Based on its health functionality, β-1,3-1,6-glucan is an interesting material as both food and medicine.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008019 Life Style Typical way of life or manner of living characteristic of an individual or group. (From APA, Thesaurus of Psychological Index Terms, 8th ed) Lifestyle Factors,Life Style Induced Illness,Lifestyle,Factor, Lifestyle,Life Styles,Lifestyle Factor,Lifestyles
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D005285 Fermentation Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID. Fermentations
D005936 Glucans Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. Glucan,Polyglucose,Polyglucoses,Glucan (BO),Glucose Polymer,Polycose,Polymer, Glucose
D000084644 Aureobasidium A genus of fungi in the family Saccotheciaceae, order Dothideales, and phylum ASCOMYCOTA. Aureobasidium fungi are cosmopolitan and form black hyphae when colony is aged. Aureobasidium pullulans is best known and is one of the causative agents of PHAEOHYPHOMYCOSIS.
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
December 2021, International journal of biological macromolecules,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2017, Journal of applied glycoscience,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
December 2016, World journal of microbiology & biotechnology,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2012, Bioscience, biotechnology, and biochemistry,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2022, Journal of clinical and experimental hepatology,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2012, PloS one,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2006, Anticancer research,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
January 2013, Biomedical reports,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
December 2020, Applied microbiology and biotechnology,
Toshio Suzuki, and Kisato Kusano, and Nobuhiro Kondo, and Kouji Nishikawa, and Takao Kuge, and Naohito Ohno
December 2009, The Korean journal of parasitology,
Copied contents to your clipboard!